Henderson Molly
- SEC CIK
- 0001363812
No open-market purchases or sales filed in the past year.
Current role at each company
- PHAT Phathom Pharmaceuticals, Inc.CFO and CBOas of Apr 8, 2025
- URGN UroGen Pharma Ltd.Chief Financial Officeras of Feb 2, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Henderson Molly as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
PHAT Phathom Pharmaceuticals, Inc.
CFO and CBO14 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 16, 2022 (view filing) | May 13 | 3 days | Henderson MollyCFO and CBO | PPurchase | +6.00K | – | – | +30.0%26.0K after | |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Henderson MollyCFO and CBO | SSale | −2.16K | $9.60 | −$20.7K | −4.7%43.3K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Henderson MollyCFO and CBO | SSale | −2.03K | $8.53 | −$17.3K | −2.6%76.0K after | |
| Apr 7, 2023 (view filing) | Apr 6 | 1 day | Henderson MollyCFO and CBO | SSale | −3.44K | $7.27 | −$25.0K | −4.5%72.6K after | 10b5-1 |
| May 23, 2023 (view filing) | May 22 | 1 day | Henderson MollyCFO and CBO | SSale | −2.11K | $12.87 | −$27.2K | −2.9%70.5K after | 10b5-1 |
| Jun 5, 2023 (view filing) | Jun 2 | 3 days | Henderson MollyCFO and CBO | SSale | −1.96K | $11.41 | −$22.4K | −2.8%68.5K after | 10b5-1 |
| Nov 3, 2023 (view filing) | Nov 1 | 2 days | Henderson MollyCFO and CBO | SSale | −12.5K | $8.88 | −$110.9K | −10.6%105.2K after | 2 lots |
| Nov 21, 2023 (view filing) | Nov 20 | 1 day | Henderson MollyCFO and CBO | SSale | −2.13K | $7.24 | −$15.4K | −2.0%103.1K after | |
| Jan 22, 2024 (view filing) | Jan 19 | 3 days | Henderson MollyCFO and CBO | SSale | −6.31K | $7.75 | −$48.9K | −6.0%98.7K after | |
| Apr 10, 2024 (view filing) | Apr 8 | 2 days | Henderson MollyCFO and CBO | SSaleCommon Stoock | −3.44K | $11.10 | −$38.1K | −3.5%95.3K after |
URGN UroGen Pharma Ltd.
Chief Financial Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 2, 2021 (view filing) | Nov 30 | 2 days | Henderson MollyChief Financial Officer | SSale | −2.59K | $12.03 | −$31.1K | −34.5%4.91K after | |
| Feb 2, 2022 (view filing) | Jan 31 | 2 days | Henderson MollyChief Financial Officer | SSale | −331 | $7.58 | −$2.51K | −5.9%5.25K after |